



**EFPIA Code Disclosure
2021 Self-Certification Letter
Teva Pharmaceuticals Europe BV**

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Teva Pharmaceutical Europe BV works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway. In the same way, the pharmaceutical industry works with Patient Organizations (POs). This collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs, HCOs, and POs aims to build understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Teva Pharmaceutical Europe BV hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Teva Pharmaceutical Europe BV certifies that its disclosures of ToVs:

- have been completed in each EFPIA country where Teva Pharmaceutical Europe BV operates;
- include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA; and
- are further described in the respective country's Methodological Note.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Teva Pharmaceutical Europe BV certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).



Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Teva Pharmaceutical Europe BV certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate; and
- Decisions of local code authorities in response to the COVID19 pandemic.

Ensuring compliance with Data Privacy Obligations


Teva Pharmaceutical Europe BV certifies that its disclosure complies with the Data Privacy obligations.

Date: June 30, 2021

Name of signatory: Richard Daniell

Position in the Company: Executive Vice President
Teva Pharmaceuticals Europe BV

Signature:

DocuSigned by:

F6D73ABE0D4B4C6...